Current treatment of myeloproliferative neoplasias: three scenarios
Med Clin (Barc). 2020 Feb 28;154(4):131-133.
doi: 10.1016/j.medcli.2019.05.009.
Epub 2019 Jul 24.
[Article in
English,
Spanish]
Affiliations
- 1 Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, España. Electronic address: bxicoy@iconcologia.net.
- 2 Laboratorio Hematología, Biología Molecular,, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, España.
No abstract available
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Drug Resistance, Neoplasm
-
Humans
-
Imatinib Mesylate / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Myeloproliferative Disorders / therapy*
-
Niacinamide / analogs & derivatives
-
Niacinamide / therapeutic use
-
Nitriles
-
Polycythemia Vera / drug therapy
-
Primary Myelofibrosis / drug therapy
-
Primary Myelofibrosis / genetics
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / therapeutic use
-
Pyrimidines
-
Recurrence
-
Remission Induction
-
Thrombocythemia, Essential / drug therapy
-
Time Factors
-
Withholding Treatment
Substances
-
Antineoplastic Agents
-
Nitriles
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
asciminib
-
Niacinamide
-
ruxolitinib
-
Imatinib Mesylate